The Bones Don’t Lie: PFAS Effects on Skeletal Health
The skeletal system—providing structure, protection, and mineral storage for the body—may be an underappreciated target of PFAS toxicity. PFAS compounds accumulate in bone matrix, interact with the hormone systems governing bone metabolism (including estrogen, parathyroid hormone, and vitamin D signaling), and have been associated in epidemiological studies with reduced bone mineral density and increased fracture risk. For the millions of people at risk for osteoporosis—particularly postmenopausal women—PFAS exposure may represent a modifiable environmental risk factor that has not yet been incorporated into clinical practice guidelines for bone health management.
PFAS Accumulation in Bone and Mechanistic Effects
Bone tissue contains a mineral matrix (hydroxyapatite) and an organic protein matrix (primarily type I collagen) that can both interact with PFAS compounds. Studies measuring PFAS in bone samples from surgical procedures and postmortem specimens have detected PFAS at concentrations reflecting systemic body burden, with fluoride derived from PFAS metabolism potentially incorporating into the hydroxyapatite crystal lattice. In animal studies, PFAS exposure has been associated with altered bone mineral density, changes in bone collagen structure, and modified osteoblast and osteoclast activity—the cell types governing bone formation and resorption respectively.
Hormonal mediation of PFAS bone effects is particularly relevant for postmenopausal women, whose bone health is already vulnerable to declining estrogen levels. PFAS compounds interact with estrogen receptor signaling at multiple levels, potentially amplifying the bone loss associated with estrogen deficiency. Thyroid hormone disruption—a well-characterized PFAS health effect—also affects bone metabolism: both hypothyroidism and hyperthyroidism alter bone turnover rates, suggesting an indirect skeletal pathway through which PFAS thyroid effects translate to bone health consequences.
Epidemiological Evidence from Human Studies
NHANES data analyses have found inverse associations between serum PFAS concentrations and bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DEXA) in U.S. women—with higher PFAS blood levels associated with lower BMD at hip and lumbar spine sites. The association appears strongest in postmenopausal women, consistent with the estrogen-mediated mechanism hypothesis. A prospective study in Denmark found associations between maternal PFAS exposure during pregnancy and altered fetal bone development markers, suggesting that bone effects may begin in utero during critical skeletal development windows.
Studies of occupationally exposed populations—including workers at fluoropolymer manufacturing facilities with high historical PFAS exposures—have not yet specifically reported bone health outcomes, representing a research gap that future occupational health surveillance programs should address. The C8 Health Project cohort—with detailed health data including radiological studies—has the potential to provide the highest-quality prospective bone health data for a high-PFAS-exposure population, though bone health outcomes have received less attention than cancer and cardiovascular endpoints in published analyses.
Clinical and Public Health Implications
Bone health clinicians managing patients with unexplained osteoporosis or accelerated bone loss—particularly in women without traditional risk factors—may find value in considering PFAS exposure history as part of a comprehensive environmental assessment. For women in PFAS-contaminated communities, bone density monitoring as part of PFAS health surveillance programs provides both individual clinical benefit and population-level data to better characterize PFAS-bone relationships. The potential for dietary calcium supplementation and vitamin D to partially mitigate PFAS bone effects—by supporting bone formation pathways that PFAS may undermine—warrants clinical investigation, though current evidence is insufficient to recommend supplementation specifically for PFAS-related bone protection.